4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Elicio Therapeutics, Inc. (ELTX) operates in the Biotechnology industry and is headquartered in Boston, United States with about 33 employees. Its market capitalization is roughly $67 million. In the fiscal year ended 2025-12-31, ELTX reported $0M in revenue and ($40M) in net income.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($37M) | ($45M) | ($36M) | ($24M) |
| Net Income | ($40M) | ($52M) | ($35M) | ($28M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($11M) | ($9M) | ($8M) | ($10M) | ($11M) | — |
| Net Income | ($12M) | ($8M) | ($10M) | ($11M) | ($11M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $26M | $28M | $27M | $23M | — |
| Total Liabilities | $24M | $40M | $16M | $125M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ELTX viewer.
About TickerBase · Data methodology & sources